Skip to main navigation
Logo

Investors

Press Releases

Date Title View
January 20, 2022
AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease
January 7, 2022
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 12 of 12

Shareholder Tools

Print Page
Email Alerts
RSS Feeds
Investor Contact
  • Investor Overview
  • News & Events
    • Press Releases
    • Events
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Committee Composition
  • Financial Information
    • SEC Filings
  • IR Resources
    • Email Alerts
    • Contact IR
  • More
    • About Us
      • Mission
      • Leadership
      • Board of Directors
      • Founders
      • Partners
      • Expanded Access Policy
    • Technology
    • Pipeline
      • Epetraborole
      • NTM
    • Investors
      • Investor Overview
      • News & Events
        • Press Releases
        • Events
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Committee Composition
      • Financial Information
        • SEC Filings
      • IR Resources
        • Email Alerts
        • Contact IR
    • Careers
      • Job Opportunities
      • Values
      • Benefits
    • Contact
    • Home
    • About Us
      • Mission
      • Leadership
      • Board of Directors
      • Founders
      • Partners
      • Expanded Access Policy
    • Technology
    • Pipeline
      • Epetraborole
      • NTM
    • Investors
      • Investor Overview
      • News & Events
        • Press Releases
        • Events
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Committee Composition
      • Financial Information
        • SEC Filings
      • IR Resources
        • Email Alerts
        • Contact IR
    • Careers
      • Job Opportunities
      • Values
      • Benefits
    • Contact
    • Privacy Policy
    • Terms of Use
    Logo

    Location
    1800 El Camino Real, Suite D
    Menlo Park, CA 94027
    Phone: 650-331-9090

    General Information
    info@an2therapeutics.com

    Investor & Media Inquiries
    info@an2therapeutics.com

    Job Inquiries
    careers@an2therapeutics.com

    Business Development Contact
    partner@an2therapeutics.com

    linkedin

    • Privacy Policy
    • Terms of Use
    © 2022 AN2 Therapeutics All rights reserved.
    Website Design: Hane Chow, Inc.